…
Applied Biosciences Corp. focuses on the development and commercialization of synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas. It delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing, as well as testing and analytics capabilities to its customers. The company was incorporated in 2014 and is based in Beverly Hills, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly available information for Applied Biosciences Corp (OTC: APPB) is limited and does not clearly detail the company's core operations or verified product portfolio. Because disclosures are sparse, long-term growth drivers are not well documented and any potential upside would depend on successful execution, clearer regulatory filings, and access to financing, which may appeal only to investors comfortable with high informational and liquidity risk.
Material risks include minimal public disclosure, low trading liquidity, limited or outdated financial reporting, potential dilution from future financings, and regulatory or operational uncertainty typical of OTC microcap issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
| Income before tax | -2.68M | -2.39M | -0.52M | -0.10M |
| Minority interest | 1.14M | -0.01M | 0.00M | 0.00M |
| Net income | -2.63M | -2.38M | -0.52M | -0.10M |
| Selling general administrative | 2.79M | 1.31M | 0.16M | 0.10M |
| Gross profit | 0.19M | 0.04M | 0.04M | 0.00M |
| Reconciled depreciation | 0.04M | 0.22M | - | - |
| Ebit | -2.65M | -1.49M | -0.14M | -0.10M |
| Ebitda | -1.99M | -1.27M | - | - |
| Non operating income net other | 0.00M | 0.00M | 0.00M | 0.00M |
| Operating income | -2.65M | -1.49M | -0.14M | -0.10M |
| Other operating expenses | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest expense | 0.65M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.65M | - | - | - |
| Extraordinary items | 0.00M | 0.00M | 0.00M | 0.00M |
| Non recurring | 0.00M | 0.00M | 0.00M | 0.00M |
| Other items | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.71M | 0.20M | 0.05M | 0.00M |
| Total operating expenses | 3.35M | 1.69M | 0.19M | 0.10M |
| Cost of revenue | 0.52M | 0.16M | 0.01M | 0.00M |
| Total other income expense net | 0.62M | -0.89M | -0.38M | 0.00M |
| Discontinued operations | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income from continuing ops | -2.68M | -2.39M | -0.52M | -0.10M |
| Net income applicable to common shares | -2.63M | -2.38M | -0.52M | -0.10M |
| Preferred stock and other adjustments | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
| Total assets | 3.65M | 0.71M | 1.68M | 0.00M |
| Intangible assets | 0.00M | 0.00M | 1.12M | 0.00M |
| Other current assets | 0.00M | 0.00M | 0.00M | 0.00M |
| Total liab | 0.37M | 0.04M | 0.03M | 0.01M |
| Total stockholder equity | 2.13M | 0.68M | 1.64M | -0.01M |
| Deferred long term liab | 0.00M | 0.00M | 0.00M | 0.00M |
| Other current liab | 0.00M | 0.00M | 0.00M | 0.00M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | - | - | - |
| Retained earnings | -5.53M | -2.90M | -0.53M | -0.01M |
| Other liab | 0.00M | 0.00M | 0.00M | 0.00M |
| Good will | 1.94M | 0.00M | 0.00M | 0.00M |
| Other assets | 0.01M | 0.01M | 0.00M | 0.00M |
| Cash | 0.05M | 0.06M | 0.21M | 0.00M |
| Total current liabilities | 0.37M | 0.04M | 0.03M | 0.01M |
| Short term debt | 0.00M | 0.00M | 0.00M | 0.00M |
| Short long term debt | 0.03M | 0.00M | 0.00M | 0.00M |
| Other stockholder equity | 0.77M | 0.53M | 0.43M | -0.00M |
| Property plant equipment | 0.45M | 0.00M | 0.00M | 0.00M |
| Total current assets | 0.35M | 0.23M | 0.26M | 0.00M |
| Long term investments | 0.90M | 0.47M | 0.30M | 0.00M |
| Net tangible assets | 0.19M | 0.68M | 0.52M | -0.01M |
| Short term investments | 0.00M | 0.00M | 0.00M | 0.00M |
| Net receivables | 0.16M | 0.01M | 0.01M | - |
| Long term debt | 0.00M | 0.00M | 0.00M | 0.00M |
| Inventory | 0.08M | 0.03M | 0.02M | 0.00M |
| Accounts payable | 0.28M | 0.02M | 0.01M | 0.00M |
| Total permanent equity | 0.00M | 0.00M | 0.00M | 0.00M |
| Noncontrolling interest in consolidated entity | 0.00M | 0.00M | 0.00M | 0.00M |
| Temporary equity redeemable noncontrolling interests | 0.00M | 0.00M | 0.00M | 0.00M |
| Accumulated other comprehensive income | 0.00M | 0.00M | 0.00M | 0.00M |
| Additional paid in capital | 0.00M | 0.00M | 0.00M | 0.00M |
| Common stock total equity | 0.00M | 0.00M | 0.00M | 0.00M |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | 0.00M | 0.00M | 0.00M | 0.00M |
| Treasury stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Accumulated amortization | 0.00M | 0.00M | 0.00M | 0.00M |
| Non currrent assets other | 0.01M | 0.01M | 1.42M | 0.00M |
| Deferred long term asset charges | 0.00M | 0.00M | 0.00M | 0.00M |
| Non current assets total | 3.30M | 0.48M | 1.42M | 0.00M |
| Capital lease obligations | 0.00M | 0.00M | 0.00M | 0.00M |
| Long term debt total | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 |
| Investments | -0.71M | -0.17M | -0.30M | -0.30M |
| Change to liabilities | 0.04M | 0.00M | 0.02M | 0.03M |
| Total cashflows from investing activities | -0.71M | -0.17M | -0.78M | -0.78M |
| Net borrowings | 1.53M | 1.53M | 1.53M | 0.07M |
| Total cash from financing activities | 1.60M | 0.69M | 1.13M | 0.07M |
| Change to operating activities | 0.29M | -0.00M | -0.02M | -0.02M |
| Net income | -2.63M | -2.38M | -0.52M | -0.10M |
| Change in cash | -0.01M | -0.15M | 0.21M | 0.21M |
| Begin period cash flow | 0.06M | 0.21M | 0.00M | - |
| End period cash flow | 0.05M | 0.06M | 0.21M | - |
| Total cash from operating activities | -0.91M | -0.67M | -0.14M | -0.07M |
| Issuance of capital stock | 0.07M | - | - | - |
| Depreciation | 0.04M | 0.22M | 0.02M | 0.02M |
| Other cashflows from investing activities | 0.00M | 0.00M | 0.00M | 0.00M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | -0.05M | -0.01M | -0.02M | -0.02M |
| Change to account receivables | -0.02M | -0.01M | -0.01M | -0.01M |
| Sale purchase of stock | 0.00M | -0.10M | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to netincome | 0.93M | 1.49M | 0.38M | 0.38M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash flows other operating | 0.00M | 0.00M | 0.00M | 0.00M |
| Exchange rate changes | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash and cash equivalents changes | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.26M | -0.01M | - | - |
| Stock based compensation | 1.06M | - | - | - |
| Other non cash items | 0.85M | 0.61M | - | - |
| Free cash flow | -0.91M | -0.68M | - | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| APPB Applied Biosciences Corp |
- -% |
0.00 | - | - | 0.00 | 0.31 | 0.08 | -0.03 |
| MKKGY Merck KGaA ADR |
-0.23 0.70% |
32.85 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.42 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
21.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-0.54 1.24% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Applied Biosciences Corp. focuses on the development and commercialization of synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas. It delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing, as well as testing and analytics capabilities to its customers. The company was incorporated in 2014 and is based in Beverly Hills, California.
9701 Wilshire Boulevard, Beverly Hills, CA, United States, 90212
310 356 7374
25
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher Michael Bridges | Pres | 1979 |
| Mr. David Fiene | Controller | 1971 |
| Mr. Christopher Michael Bridges | President | 1979 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.